お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
市場調査レポート
商品コード
980718

ワクチン市場:技術別、適応別、最終用途別:世界の機会分析と業界予測(2020~2027年)

Vaccine Market By Technology, Indication, and End Use : Global Opportunity Analysis and Industry Forecast, 2020-2027

出版日: | 発行: Allied Market Research | ページ情報: 英文 294 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.58円
ワクチン市場:技術別、適応別、最終用途別:世界の機会分析と業界予測(2020~2027年)
出版日: 2020年11月20日
発行: Allied Market Research
ページ情報: 英文 294 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のワクチンの市場規模は2019年に324億6,300万米ドルとなりました。同市場は、2020年から2027年にかけ6.6%のCAGRで拡大し、2027年までに541億6,800万米ドルに達すると予測されています。

ワクチンは、患者の獲得免疫をつくるために投与される生物学的製剤です。ワクチンの投与は、特定の病原体に対する免疫反応を高めるのに役立ちます。予防接種は、さまざまな国で人々の健康を維持する上で重要な役割を果たします。したがって、それらはさまざまな国の疾病予防戦略で使用されます。ウイルス感染症と細菌感染症の両方の発生が増加しているため、ワクチンの需要は過去数年間で増加しています。予防接種は主にさまざまな年齢の人々に提供され、生涯の免疫系を改善し、さまざまな形態の感染症に対する防御をします。

ワクチン市場は、国の予防接種プログラムによって世界中のいくつかの国で採用が増加しているため、予測期間中に大幅な市場成長を経験すると予測されます。さらに、いくつかの国での肺炎球菌性髄膜炎菌性疾患の発生の急増は、髄膜炎菌ワクチンの需要の急増につながり、市場の成長をさらに促進しています。ただし、新しいワクチンの承認と汚染によるいくつかの製品リコールに関する厳しい政府規制が市場の成長を妨げると予想されます。対照的に、新興市場における高い人口基盤とヘルスケア費の世界の増加は、髄膜炎菌ワクチン市場に大きな成長機会を提供します。

地域別では、市場は北米、欧州、アジア太平洋、およびLAMEAに分類されます。北米は2019年に最大の市場シェアを占め、予測期間を通じてその優位性を維持すると予想されます。これは、病院や診療所に設備が整っており資金が豊富なこと、ワクチン製品の高い採用率、高度なヘルスケアインフラなどの要因によるものです。さらに、米国はワクチン接種に対する意識が高いため、市場のトップ企業が標的とする地域となっています。しかし、アジア太平洋地域は、ヘルスケア施設の改善、利用可能な可処分所得の増加、および急速に発展する経済状況により、最大の成長可能性を秘めた収益性の高い地域となると予想されます。

当レポートでは、ワクチン市場について調査し、市場の概要とともに、技術別、適応別、最終用途別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
    • 2019年の主な成功戦略
  • トッププレーヤーのポジショニング
    • 主な投資ポケット
  • ワクチン業界/市場を形作る主要な力
  • 市場力学
    • 促進要因
      • 感染症の有病率の増加
      • 世界中の予防接種プログラムの急増
      • 新しいワクチンを開発するための研究開発活動の増加
    • 抑制要因
      • ワクチン製造に必要なより長いタイムライン
      • ワクチンの開発に伴う高コスト
    • 市場機会
      • 新興市場における成長機会
      • ヘルスケア費の増加
    • 影響分析
  • ワクチン市場におけるCOVID-19の影響分析
    • 概要
    • 影響分析

第4章 ワクチン市場:技術別

  • 概要
    • 市場規模と予測
  • 組換えおよび抱合型ワクチン
    • 主要な市場動向、成長要因、および機会
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 不活化ワクチン
    • 主要な市場動向、成長要因、および機会
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 弱毒化生ワクチン
    • 主要な市場動向、成長要因、および機会
    • 市場規模と予測:地域別
    • 市場分析:国別
  • トキソイドワクチン
    • 主要な市場動向、成長要因、および機会
    • 市場規模と予測:地域別
    • 市場分析:国別
  • その他のワクチン
    • 主要な市場動向、成長要因、および機会
    • 市場規模と予測:地域別
    • 市場分析:国別

第5章 世界のワクチン市場:適応別

  • 概要
    • 市場規模と予測
  • 肺炎球菌感染症
    • 主要な市場動向、成長要因、および機会
    • 市場規模と予測:地域別
    • 市場分析:国別
  • インフルエンザ
    • 主要な市場動向、成長要因、および機会
    • `市場規模と予測:地域別
    • 市場分析:国別
  • ヒトパピローマウイルス
    • 主要な市場動向、成長要因、および機会
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 髄膜炎菌性疾患
    • 主要な市場動向、成長要因、および機会
    • 市場規模と予測:地域別
    • 市場分析:国別
  • ロタウイルス
    • 主要な市場動向、成長要因、および機会
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 水痘、はしか、おたふく風邪、風疹(MMR)
    • 主要な市場動向、成長要因、および機会
    • 市場規模と予測:地域別
    • 市場分析:国別
  • ジフテリア、百日咳、破傷風(DPT)
    • 主要な市場動向、成長要因、および機会
    • 市場規模と予測:地域別
    • 市場分析:国別
  • ポリオ
    • 主要な市場動向、成長要因、および機会
    • 市場規模と予測:地域別
    • 市場分析:国別
  • 肝炎
    • 主要な市場動向、成長要因、および機会
    • 市場規模と予測:地域別
    • 市場分析:国別
  • その他の適応症
    • 主要な市場動向、成長要因、および機会
    • 市場規模と予測:地域別
    • 市場分析:国別

第6章 ワクチン市場:エンドユーザー別

  • 概要
    • 市場規模と予測
  • 小児用ワクチン
    • 市場規模と予測
    • 市場分析:国別
  • 成人用ワクチン
    • 市場規模と予測
    • 市場分析:国別
  • 旅行者用ワクチン
    • 市場規模と予測
    • 市場分析:国別

第7章 世界のワクチン市場:地域別

  • 概要
    • 市場規模と予測
  • 北米
    • 主要な市場動向、成長要因、および機会
    • 市場規模と予測:国別
    • 市場規模と予測:テクノロジー別
    • 市場規模と予測:適応別
    • 市場規模と予測:エンドユーザー別
      • 米国の市場規模と予測:テクノロジー別
      • 市場規模と予測:適応別
      • 市場規模と予測:エンドユーザー別
      • メキシコの市場規模と予測:技術別
      • メキシコの市場規模と予測:適応別
      • メキシコの市場規模と予測:エンドユーザー別
      • カナダの市場規模と予測:技術別
      • カナダの市場規模と予測:適応別
      • カナダの市場規模と予測:エンドユーザー別
  • 欧州
    • 主要な市場動向、成長要因、および機会
    • 市場規模と予測:国別
    • 市場規模と予測:テクノロジー別
    • 市場規模と予測:適応別
    • 市場規模と予測:エンドユーザー別
      • ドイツの市場規模と予測:技術別
      • ドイツの市場規模と予測:適応別
      • ドイツの市場規模と予測:エンドユーザー別
      • フランスの市場規模と予測:技術別
      • フランスの市場規模と予測:適応別
      • フランスの市場規模と予測:エンドユーザー別
      • 英国の市場規模と予測:テクノロジー別
      • 英国の市場規模と予測:適応別
      • 英国の市場規模と予測:エンドユーザー別
      • イタリアの市場規模と予測:技術別
      • イタリアの市場規模と予測:適応別
      • イタリアの市場規模と予測:エンドユーザー別
      • スペインの市場規模と予測:技術別
      • スペインの市場規模と予測:適応別
      • スペインの市場規模と予測:エンドユーザー別
      • その他欧州の市場規模と予測:技術別
      • その他欧州の市場規模と予測:適応別
      • その他欧州の市場規模と予測:エンドユーザー別
  • アジア太平洋
    • 主要な市場動向、成長要因、および機会
    • 市場規模と予測:国別
    • 市場規模と予測:テクノロジー別
    • 市場規模と予測:適応別
    • 市場規模と予測:エンドユーザー別
      • 日本の市場規模と予測:技術別
      • 日本の市場規模と予測:適応別
      • 日本の市場規模と予測:エンドユーザー別
      • 中国の市場規模と予測:技術別
      • 中国の市場規模と予測:適応別
      • 中国の市場規模と予測:エンドユーザー別
      • インドの市場規模と予測:技術別
      • インドの市場規模と予測:適応別
      • インドの市場規模と予測:エンドユーザー別
      • オーストラリアの市場規模と予測:テクノロジー別
      • オーストラリアの市場規模と予測:適応別
      • オーストラリアの市場規模と予測:エンドユーザー別
      • その他アジア太平洋地域の市場規模と予測:テクノロジー別
      • その他アジア太平洋地域の市場規模と予測:適応別
      • その他アジア太平洋地域の市場規模と予測:エンドユーザー別
  • LAMEA
    • 主要な市場動向、成長要因、および機会
    • 市場規模と予測:国別
    • 市場規模と予測:テクノロジー別
    • 市場規模と予測:適応別
    • 市場規模と予測:エンドユーザー別
      • ブラジルの市場規模と予測:技術別
      • ブラジルの市場規模と予測:適応別
      • ブラジルの市場規模と予測:エンドユーザー別
      • サウジアラビアの市場規模と予測:技術別
      • サウジアラビアの市場規模と予測:適応別
      • サウジアラビアの市場規模と予測:エンドユーザー別
      • 南アフリカの市場規模と予測:技術別
      • 南アフリカの市場規模と予測:適応別
      • 南アフリカの市場規模と予測:エンドユーザー別
      • LAMEAの残りの市場規模と予測:技術別
      • LAMEAの残りの市場規模と予測:適応別
      • LAMEAの残りの市場規模と予測:エンドユーザー別

第8章 企業プロファイル

  • AstraZeneca plc.
  • CSL Limited
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc.
  • Johnson & Johnson
  • MERCK & CO. INC.
  • NOVAVAX, INC.
  • PFIZER INC.
  • Sanofi S.A.
  • SERUM INSTITUTE OF INDIA PVT. LTD
図表

LIST OF TABLES

  • TABLE 01.GLOBAL VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 02.RECOMBINANT & CONJUGATE VACCINE MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 03.INACTIVATED VACCINE, BY REGION, 2019-2027 ($MILLION)
  • TABLE 04.LIVE ATTENUATED VACCINE, BY REGION, 2019-2027 ($MILLION)
  • TABLE 05.TOXOID VACCINE, BY REGION, 2019-2027 ($MILLION)
  • TABLE 06.VACCINE MARKET FOR OTHER VACCINES, BY REGION, 2019-2027 ($MILLION)
  • TABLE 07.GLOBAL VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 08.VACCINE MARKET FOR PNEUMOCOCCAL DISEASE, BY REGION, 2019-2027 ($MILLION)
  • TABLE 09.VACCINE MARKET FOR INFLUENZA, BY REGION, 2019-2027 ($MILLION)
  • TABLE 10.VACCINE MARKET FOR HUMAN PAPILLOMA VIRUS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 11.VACCINE MARKET FOR MENINGOCOCCAL DISEASE, BY REGION, 2019-2027 ($MILLION)
  • TABLE 12.VACCINE MARKET FOR ROTAVIRUS DISEASE, BY REGION, 2019-2027 ($MILLION)
  • TABLE 13.VACCINE MARKET FOR VARICELLA, MEASLES, MUMPS, AND RUBELLA (MMR), BY REGION, 2019-2027 ($MILLION)
  • TABLE 14.VACCINE MARKET FOR DIPHTHERIA, PERTUSSIS, & TETANUS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 15.VACCINE MARKET FOR POLIO, BY REGION, 2019-2027 ($MILLION)
  • TABLE 16.VACCINE MARKET FOR HEPATITIS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 17.VACCINE MARKET FOROTHER INDICATION, BY REGION, 2019-2027 ($MILLION)
  • TABLE 18.GLOBAL VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 19.VACCINE MARKET FOR PEDIATRIC, BY REGION, 2019-2027 ($MILLION)
  • TABLE 20.VACCINE MARKET FOR ADULTS VACCINES, BY REGION, 2019-2027 ($MILLION)
  • TABLE 21.VACCINE MARKET FOR TRAVELERS VACCINES, BY REGION, 2019-2027 ($MILLION)
  • TABLE 22.VACCINE MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 23.NORTH AMERICA VACCINE MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 24.NORTH AMERICA VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 25.NORTH AMERICA VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 26.NORTH AMERICA MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 27.U.S. VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 28.U.S. VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 29.U.S. VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 30.MEXICO VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 31.MEXICO VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 32.MEXICO VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 33.CANADA VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 34.CANADA VACCINE MARKET, BY INDICATION , 2019-2027 ($MILLION)
  • TABLE 35.CANADA VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 36.EUROPE VACCINE MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 37.EUROPE VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 38.EUROPE VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 39.EUROPE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 40.GERMANY VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 41.GERMANY VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 42.GERMANY VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 43.FRANCE VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 44.FRANCE VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 45.FRANCE VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 46.UK VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 47.UK VACCINE MARKET, BY INDICATION , 2019-2027 ($MILLION)
  • TABLE 48.UK VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 49.ITALY VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 50.ITALY VACCINE MARKET, BY INDICATION , 2019-2027 ($MILLION)
  • TABLE 51.ITALY VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 52.SPAIN VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 53.SPAIN VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 54.SPAIN VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 55.REST OF EUROPE VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 56.REST OF EUROPE VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 57.REST OF EUROPE VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 58.ASIA-PACIFIC VACCINE MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 59.ASIA-PACIFIC VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 60.ASIA-PACIFIC VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 61.ASIA-PACIFIC MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 62.JAPAN VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 63.JAPAN VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 64.JAPAN VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 65.CHINA VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 66.CHINA VACCINE MARKET, BY INDICATION , 2019-2027 ($MILLION)
  • TABLE 67.CHINA VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 68.INDIA VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 69.INDIA VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 70.INDIA VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 71.AUSTRALIA VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 72.AUSTRALIA VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 73.AUSTRALIA VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 74.REST OF ASIA-PACIFIC VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 75.REST OF ASIA-PACIFIC VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 76.REST OF ASIA-PACIFIC VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 77.LAMEA VACCINE MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 78.LAMEA VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 79.LAMEA VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 80.LAMEA MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 81.BRAZIL VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 82.BRAZIL VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 83.BRAZIL VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 84.SAUDI ARABIA VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 85.SAUDI ARABIA VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 86.SAUDI ARABIA VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 87.SOUTH AFRICA VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 88.SOUTH AFRICA VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 89.SOUTH AFRICA VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 90.REST OF LAMEA VACCINE MARKET, BY TECHNOLOGY, 2019-2027 ($MILLION)
  • TABLE 91.REST OF LAMEA VACCINE MARKET, BY INDICATION, 2019-2027 ($MILLION)
  • TABLE 92.REST OF LAMEA VACCINE MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 93.ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 94.ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 95.CSL: COMPANY SNAPSHOT
  • TABLE 96.CSL: OPERATING SEGMENTS
  • TABLE 97.CSL: PRODUCT PORTFOLIO
  • TABLE 98.EMERGENT SOLUTIONS: COMPANY SNAPSHOT
  • TABLE 99.EMERGENT SOLUTIONS: OPERATING SEGMENTS
  • TABLE 100.EMERGENT SOLUTIONS: PRODUCT PORTFOLIO
  • TABLE 101.GSK: COMPANY SNAPSHOT
  • TABLE 102.GSK: OPERATING SEGMENTS
  • TABLE 103.GSK: PRODUCT PORTFOLIO
  • TABLE 104.J&J: COMPANY SNAPSHOT
  • TABLE 105.J&J: OPERATING SEGMENTS
  • TABLE 106.J&J: PRODUCT PORTFOLIO
  • TABLE 107.MERCK: COMPANY SNAPSHOT
  • TABLE 108.MERCK: OPERATING SEGMENTS
  • TABLE 109.MERCK: PRODUCT PORTFOLIO
  • TABLE 110.NOVAVAX: COMPANY SNAPSHOT
  • TABLE 111.NOVAVAX: PRODUCT PORTFOLIO:
  • TABLE 112.PFIZER: COMPANY SNAPSHOT
  • TABLE 113.PFIZER: OPERATING SEGMENTS
  • TABLE 114.PFIZER: PRODUCT PORTFOLIO
  • TABLE 115.SANOFI: COMPANY SNAPSHOT
  • TABLE 116.SANOFI S.A.: OPERATING SEGMENTS
  • TABLE 117.SANOFI S.A.: PRODUCT PORTFOLIO
  • TABLE 118.SERUM INSTITUTE: COMPANY SNAPSHOT
  • TABLE 119.SERUM INSTITUTE: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.VACCINE MARKETSEGMENTATION
  • FIGURE 02.TOP WINNING STRATEGIES, BY DEVELOPMENTS, 2018-2020*
  • FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2020*
  • FIGURE 04.TOP WINNING STRATEGIES: COMPANY , 2018-2020
  • FIGURE 05.TOP PLAYER POSITIONING, 2019
  • FIGURE 06.TOP INVESTMENT POCKETS
  • FIGURE 07.MODERATE BARGAINING POWER OF SUPPLIER
  • FIGURE 08.MODERATEBARGAINING POWER OF BUYERS
  • FIGURE 09.MODERATE THREAT OF SUBSTITUTES
  • FIGURE 10.HIGH INTENSITY OF RIVALRY
  • FIGURE 11.HIGH THREAT OF NEW ENTRANT
  • FIGURE 12.IMPACT ANALYSIS, VACCINE MARKET
  • FIGURE 14.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR RECOMBINANT & CONJUGATE VACCINES, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 16.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR INACTIVATED VACCINE, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 18.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 19.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR TOXOID, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 20.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR OTHERS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 21.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 22.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR INFLUENZA, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 23.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR HUMAN PAPILLOMA VIRUS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 24.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 25.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR ROTAVIRUS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 26.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR VARICELLA, MEASLES, MUMPS, & RUBELLA DISEASE, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 27.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR DIPHTHERIA, PERTUSSIS, & TETANUS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 28.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR POLIO, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 29.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR HEPATITIS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 30.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 31.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR PEDIATRIC, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 32.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR ADULT, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 33.COMPARATIVE ANALYSIS OF VACCINE MARKET FOR TRAVELERS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 34.ASTRAZENECA: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 35.ASTRAZENECA: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 36.CSL: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 37.CSL REVENUE SHARE BY SEGMENTS, 2019 (%)
  • FIGURE 38.CSL LIMITED: REVENUE SHARE BY REGIONS, 2019 (%)
  • FIGURE 39.EMERGENT SOLUTIONS: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 40.EMERGENT SOLUTIONS: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 41.EMERGENT SOLUTIONS: REVENUE SHARE BY REGION, 2019(%)
  • FIGURE 42.GSK: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 43.GSK: REVENUE SHARE BY SEGMENT, 2019(%)
  • FIGURE 44.GSK: REVENUE SHARE BY REGION, 2019(%)
  • FIGURE 45.J&J: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 46.J&J: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 47.J&J: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 48.MERCK: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 49.MERCK: REVENUE SHARE BY SEGMENTS, 2019 (%)
  • FIGURE 50.MERCK: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 51.NOVAVAX: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 52.PFIZER: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 53.PFIZER: REVENUE SHARE BY SEGMENTS, 2019 (%)
  • FIGURE 54.PFIZER: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 55.SANOFI S.A.: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 56.SANOFI: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 57.SANOFI: REVENUE SHARE BY REGION, 2019(%)
目次
Product Code: A00168

Title:
Vaccine Market By Technology (Conjugate Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, and Other Vaccines), Indication (Pneumococcal Disease, Influenza, Human Papilloma Virus, Meningococcal Disease, Rotavirus, Varicella, Diphtheria, Pertussis, & Tetanus {DPT}, Polio, Hepatitis, Measles, Mumps, & Rubella {MMR}, and Other Indications), and End Use (Pediatric Vaccines, Adult Vaccines, and Traveler Vaccines): Global Opportunity Analysis and Industry Forecast, 2020-2027.

The global vaccine market accounted for $32,463 million in 2019 and is expected to reach $54,168 million by 2027, registering a CAGR of 6.6% from 2020 to 2027.

Vaccine is a biological preparation that is administered to produce acquired immunity in patients. Administration of vaccines aids to enhance the immune response against a specific pathogen. Vaccinations play a key role in sustaining people's health across different countries; hence, they are used in various national disease-prevention strategies. Due to the increased occurrence of both viral and bacterial infectious diseases, the demand for vaccines has grown over the past few years. Vaccinations are primarily provided to people of different ages, improving their immune system during their lives and ensuring defense against various forms of infectious diseases.

It is estimated that vaccine market is expected to experience significant market growth during the forecast period as there has been an increase in adoption in several countries across the globe by national immunization programs. In addition, surge in pneumococcal, meningococcal disease outbreaks in several countries has led to upsurge in demand for meningococcal vaccines, which further facilitate the growth of the market. However, stringent government regulations for the approval of new vaccines and recall of several products due to contamination are expected to impede the market growth. In contrast, high population base in emerging markets and global increase in healthcare spending provides significant growth opportunities for the meningococcal vaccine market.

Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the largest market share in 2019, and is expected to retain its dominance throughout the forecast period. This is attributed to factors such as well-equipped & better financed hospitals & clinics, high adoption rate for vaccine products, and sophisticated healthcare infrastructure. Moreover, the U.S. is the target area for top players in the market, owing to high awareness about vaccination. However, Asia-Pacific is expected to emerge as a lucrative area with maximum growth potential due to improvement in healthcare facilities, available disposable income, and rapidly developing economic conditions.

The global vaccine market is segmented on the basis of technology, indication, end user, and region. Depending on technology, the market is classified into recombinant & conjugate vaccines, live attenuated vaccines, inactivated vaccines, toxoid vaccines, and others. By indication, the market is classified into pneumococcal disease, influenza, human papilloma virus, meningococcal disease, rotavirus, varicella; diphtheria, pertussis, & tetanus (DPT), polio, hepatitis, measles; mumps, & rubella (MMR), and other indications. According to end user, the market is segmented into pediatric, adults, and travelers. By region, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, the UK, France, Spain, Italy, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The key players operating in the vaccine market include Serum Institute of India Pvt. Ltd., Pfizer, Johnson & Johnson, AstraZenecea, GlaxoSmithKline plc, Sanofi Aventis, Merck & Co., Inc., Emergent BioSolutions Inc., CSL Limited, Novavax, Inc.

KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.

It offers a quantitative analysis from 2019 to 2027, which is expected to enable stakeholders to capitalize on prevailing market opportunities.

A comprehensive analysis of the countries in Latin America is provided to determine the existing opportunities.

The key market players and their strategies have been analyzed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS

By Technology type

  • Recombinant & Conjugate Vaccines
  • Live Attenuated Vaccines
  • Inactivated Vaccines
  • Toxoid Vaccines
  • Others

By Indication

  • Pneumococcal Disease
  • Influenza
  • Human Papilloma Virus
  • Meningococcal Disease
  • Rotavirus
  • Varicella, Measles, Mumps, & Rubella
  • Diphtheria, Pertussis, & Tetanus {DPT}
  • Polio
  • Hepatitis
  • Other Indications

By End User

  • Pediatric
  • Adults
  • Travelers

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

  • AstraZenecea
  • CSL Limited
  • Emergent BioSolutions Inc.
  • GSK
  • "Johnson &
  • Johnson"
  • Merck & Co., Inc.
  • Novartis
  • Novavax, Inc.
  • Pfizer
  • Sanofi Aventis
  • Serum Institute of India Ltd

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
    • 1.2.1.List of key players profiled in the report
  • 1.3.Research methodology
    • 1.3.1.Primary research
    • 1.3.2.Secondary research
    • 1.3.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
    • 3.1.1.Top winning strategies, 2019
  • 3.2.Top player positioning
    • 3.2.1.Top investment pockets
  • 3.3.Key forces shaping vaccine industry/market
  • 3.4.Market dynamics
    • 3.4.1.Drivers
      • 3.4.1.1.Increase in prevalence of infectious diseases
      • 3.4.1.2.Surge in immunization programs across the globe
      • 3.4.1.3.Increase in R&D activities to develop new vaccine
    • 3.4.2.Restraint
      • 3.4.2.1.Longer timelines required for vaccine production
      • 3.4.2.2.High cost associated with the development of vaccine
    • 3.4.3.Opportunity
      • 3.4.3.1.Growth opportunities in the emerging markets
      • 3.4.3.2.Increase in healthcare spending
    • 3.4.4.Impact Analysis
  • 3.1.COVID-19 impact analysis on vaccine market
    • 3.1.1.Overview
    • 3.1.2.Impact analysis

CHAPTER 4:VACCINE MARKET, BY TECHNOLOGY

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Recombinant & conjugate vaccine
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast, by region
    • 4.2.3.Market analysis, by country
  • 4.3.Inactivated vaccines
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast, by region
    • 4.3.3.Market analysis, by country
  • 4.4.Live attenuated vaccines
    • 4.4.1.Key market trends, growth factors, and opportunities
    • 4.4.2.Market size and forecast, by region
    • 4.4.3.Market analysis, by country
  • 4.5.Toxoid vaccines
    • 4.5.1.Key market trends, growth factors, and opportunities
    • 4.5.2.Market size and forecast, by region
    • 4.5.3.Market analysis, by country
  • 4.6.Other vaccines
    • 4.6.1.Key market trends, growth factors, and opportunities
    • 4.6.2.Market size and forecast, by region
    • 4.6.3.Market analysis, by country

CHAPTER 5:GLOBAL VACCINE MARKET, BY INDICATION

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Pneumococcal disease
    • 5.2.1.Key market trends, growth factors, and opportunities
    • 5.2.2.Market size and forecast, by region
    • 5.2.3.Market analysis, by country
  • 5.3.Influenza
    • 5.3.1.Key market trends, growth factors, and opportunities
    • 5.3.2.`Market size and forecast, by region
    • 5.3.3.Market analysis, by country
  • 5.4.Human papilloma virus
    • 5.4.1.Key market trends, growth factors, and opportunities
    • 5.4.2.Market size and forecast, by region
    • 5.4.3.Market analysis, by country
  • 5.5.Meningococcal disease
    • 5.5.1.Key market trends, growth factors, and opportunities
    • 5.5.2.Market size and forecast, by region
    • 5.5.3.Market analysis, by country
  • 5.6.Rotavirus
    • 5.6.1.Key market trends, growth factors, and opportunities
    • 5.6.2.Market size and forecast, by region
    • 5.6.3.Market analysis, by country
  • 5.7.Varicella, measles, mumps, and rubella (MMR)
    • 5.7.1.Key market trends, growth factors, and opportunities
    • 5.7.2.Market size and forecast, by region
    • 5.7.3.Market analysis, by country
  • 5.8.Diptheria, pertussis, and tetanus (DPT)
    • 5.8.1.Key market trends, growth factors, and opportunities
    • 5.8.2.Market size and forecast, by region
    • 5.8.3.Market analysis, by country
  • 5.9.Polio
    • 5.9.1.Key market trends, growth factors, and opportunities
    • 5.9.2.Market size and forecast, by region
    • 5.9.3.Market analysis, by country
  • 5.10.Hepatitis
    • 5.10.1.Key market trends, growth factors, and opportunities
    • 5.10.2.Market size and forecast, by region
    • 5.10.3.Market analysis, by country
  • 5.11.Other indications
    • 5.11.1.Key market trends, growth factors, and opportunities
    • 5.11.2.Market size and forecast, by region
    • 5.11.3.Market analysis, by country

CHAPTER 6:VACCINES MARKET, BY END USER

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Pediatric vaccines
    • 6.2.1.Market size and forecast
    • 6.2.2.Market analysis, by country
  • 6.3.Adult vaccines
    • 6.3.1.Market size and forecast
    • 6.3.2.Market analysis, by country
  • 6.4.Travelers vaccines
    • 6.4.1.Market size and forecast
    • 6.4.2.Market analysis, by country

CHAPTER 7:GLOBAL VACCINE MARKET, BY REGION

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.North America
    • 7.2.1.Key market trends, growth factors, and opportunities
    • 7.2.2.Market size and forecast, by country
    • 7.2.3.Market size and forecast, by technology
    • 7.2.4.Market size and forecast, by indication
    • 7.2.5.Market size and forecast, by end user
      • 7.2.5.1.U.S. market size and forecast, by technology
      • 7.2.5.2.Market size and forecast, by indication
      • 7.2.5.3.Market size and forecast, by end user
      • 7.2.5.4.Mexico market size and forecast, by technology
      • 7.2.5.5.Mexico market size and forecast, by indication
      • 7.2.5.6.Mexico market size and forecast, by end user
      • 7.2.5.7.Canada market size and forecast, by technology
      • 7.2.5.8.Canada market size and forecast, by indication
      • 7.2.5.9.Canada market size and forecast, by end user
  • 7.3.Europe
    • 7.3.1.Key market trends, growth factors, and opportunities
    • 7.3.2.Market size and forecast, by country
    • 7.3.3.Market size and forecast, by technology
    • 7.3.4.Market size and forecast, by indication
    • 7.3.5.Market size and forecast, by end user
      • 7.3.5.1.Germany market size and forecast, by technology
      • 7.3.5.2.Germany market size and forecast, by indication
      • 7.3.5.3.Germany market size and forecast, by end user
      • 7.3.5.4.France market size and forecast, by technology
      • 7.3.5.5.France market size and forecast, by indication
      • 7.3.5.6.France market size and forecast, by end user
      • 7.3.5.7.UK market size and forecast, by technology
      • 7.3.5.8.UK market size and forecast, by indication
      • 7.3.5.9.UK market size and forecast, by end user
      • 7.3.5.10.Italy market size and forecast, by technology
      • 7.3.5.11.Italy market size and forecast, by indication
      • 7.3.5.12.Italy market size and forecast, by end user
      • 7.3.5.13.Spain market size and forecast, by technology
      • 7.3.5.14.Spain market size and forecast, by indication
      • 7.3.5.15.Spain market size and forecast, by end user
      • 7.3.5.16.Rest of Europe market size and forecast, by technology
      • 7.3.5.17.Rest of Europe market size and forecast, by indication
      • 7.3.5.18.Rest of Europe market size and forecast, by end user
  • 7.4.Asia-Pacific
    • 7.4.1.Key market trends, growth factors, and opportunities
    • 7.4.2.Market size and forecast, by country
    • 7.4.3.Market size and forecast, by technology
    • 7.4.4.Market size and forecast, by indication
    • 7.4.5.Market size and forecast, by end user
      • 7.4.5.1.Japan market size and forecast, by technology
      • 7.4.5.2.Japan market size and forecast, by indication
      • 7.4.5.3.Japan market size and forecast, by end user
      • 7.4.5.4.China market size and forecast, by technology
      • 7.4.5.5.China market size and forecast, by indication
      • 7.4.5.6.China market size and forecast, by end user
      • 7.4.5.7.India market size and forecast, by technology
      • 7.4.5.8.India market size and forecast, by indication
      • 7.4.5.9.India market size and forecast, by end user
      • 7.4.5.10.Australia market size and forecast, by technology
      • 7.4.5.11.Australia market size and forecast, by indication
      • 7.4.5.12.Australia market size and forecast, by end user
      • 7.4.5.13.Rest of Asia-Pacific market size and forecast, by technology
      • 7.4.5.14.Rest of Asia-Pacific market size and forecast, by indication
      • 7.4.5.15.Rest of Asia-Pacific market size and forecast, by end user
  • 7.5.LAMEA
    • 7.5.1.Key market trends, growth factors, and opportunities
    • 7.5.2.Market size and forecast, by country
    • 7.5.3.Market size and forecast, by technology
    • 7.5.4.Market size and forecast, by indication
    • 7.5.5.Market size and forecast, by end user
      • 7.5.5.1.Brazil market size and forecast, by technology
      • 7.5.5.2.Brazil market size and forecast, by indication
      • 7.5.5.3.Brazil market size and forecast, by end user
      • 7.5.5.4.Saudi Arabia market size and forecast, by technology
      • 7.5.5.5.Saudi Arabia market size and forecast, by indication
      • 7.5.5.6.Saudi Arabia market size and forecast, by end user
      • 7.5.5.7.South Africa market size and forecast, by technology
      • 7.5.5.8.South Africa market size and forecast, by indication
      • 7.5.5.9.South Africa market size and forecast, by end user
      • 7.5.5.10.Rest of LAMEA market size and forecast, by technology
      • 7.5.5.11.Rest of LAMEA market size and forecast, by indication
      • 7.5.5.12.Rest of LAMEA market size and forecast, by end user

CHAPTER 8:COMPANY PROFILES

  • 8.1.AstraZeneca plc.
    • 8.1.1.Company overview
    • 8.1.2.Company snapshot
    • 8.1.3.Product portfolio
    • 8.1.4.Business performance
  • 8.2.CSL Limited
    • 8.2.1.Company overview
    • 8.2.2.Company snapshot
    • 8.2.3.Operating business segments
    • 8.2.4.Product portfolio
    • 8.2.5.Business performance
  • 8.3.Emergent BioSolutions Inc.
    • 8.3.1.Company overview
    • 8.3.2.Company snapshot
    • 8.3.3.Operating business segments
    • 8.3.4.Product portfolio
    • 8.3.5.Business performance
    • 8.3.1.Key strategic moves and developments
  • 8.4.GlaxoSmithKline plc.
    • 8.4.1.Company overview
    • 8.4.2.Company snapshot
    • 8.4.3.Operating business segments
    • 8.4.4.Product portfolio
    • 8.4.5.Business performance
    • 8.4.6.Key strategic moves and developments
  • 8.5.Johnson & Johnson
    • 8.5.1.Company overview
    • 8.5.2.Company snapshot
    • 8.5.3.Operating business segments
    • 8.5.4.Product portfolio
    • 8.5.5.Business performance
    • 8.5.6.Key strategic moves and developments
  • 8.6.MERCK & CO. INC.
    • 8.6.1.Company overview
    • 8.6.2.Company snapshot
    • 8.6.3.Operating business segments
    • 8.6.4.Product portfolio
    • 8.6.5.Business performance
    • 8.6.6.Key strategic moves and developments
  • 8.7.NOVAVAX, INC.
    • 8.7.1.Company overview
    • 8.7.2.Company snapshot
    • 8.7.3.Operating business segments
    • 8.7.4.Product portfolio
    • 8.7.5.Business performance
  • 8.8.PFIZER INC.
    • 8.8.1.Company overview
    • 8.8.2.Company snapshot
    • 8.8.3.Operating business segments
    • 8.8.4.Product portfolio
    • 8.8.5.Business performance
    • 8.8.6.Key strategic moves and developments
  • 8.9.Sanofi S.A.
    • 8.9.1.Company overview
    • 8.9.2.Company snapshot
    • 8.9.3.Operating business segments
    • 8.9.4.Product portfolio
    • 8.9.5.Business performance
    • 8.9.6.Key strategic moves and developments
  • 8.10.SERUM INSTITUTE OF INDIA PVT. LTD
    • 8.10.1.Company overview
    • 8.10.2.Company snapshot
    • 8.10.3.Operating business segments
    • 8.10.4.Product portfolio
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.